Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Reau, Nancy, Robertson, Michael N., Feng, Hwa‐Ping, Caro, Luzelena, Yeh, Wendy W., Nguyen, Bach‐Yen T., Wahl, Janice, Barr, Eliav, Hwang, Peggy, Klopfer, Stephanie O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678913/
https://www.ncbi.nlm.nih.gov/pubmed/29404492
http://dx.doi.org/10.1002/hep4.1081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678913/
https://www.ncbi.nlm.nih.gov/pubmed/29404492
http://dx.doi.org/10.1002/hep4.1081

Ejemplares similares